Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center

C Girmenia, C Mercanti, V Federico, M Rea, A De Vellis, V Valle, A Micozzi, R Latagliata, M Breccia, Sg Morano, Ga Brunetti, Michela Sali, Giovanni Delogu, R Foà, G Alimena, G. Gentile

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

4 Citazioni (Scopus)

Abstract

Data derived from epidemiologic surveillance adopted at our center in hematologic and stem cell transplant patients during the 2009 influenza A (H1N1)v pandemic are reported. Of the 52 patients with influenza-like disease we observed, 37 underwent a real-time PCR evaluation and 21 had a confirmed diagnosis. Of the RT-PCR-confirmed cases, 23.8% were children (age <18 years) and 9.5% were >65 years; 47.6% presented with a pulmonary infiltrate and 33.3% with respiratory failure. Pulmonary involvement was observed more frequently in patients with comorbidities. All patients received a course of oseltamivir therapy starting an average of 1 day (range <1-2) after the onset of symptoms. No patient was transferred to the intensive care unit. The viral disease had a generally favorable outcome despite the high frequency of pulmonary involvement. A prompt clinical evaluation with an early antiviral and supportive therapy may have played a beneficial role in the outcome.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaActa Haematologica
Volume126
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents
  • Child
  • Child, Preschool
  • Female
  • Hematologic Diseases
  • Humans
  • Influenza, Human
  • Italy
  • Male
  • Middle Aged
  • Oseltamivir
  • Polymerase Chain Reaction
  • Prospective Studies
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center'. Insieme formano una fingerprint unica.

Cita questo